According to the information placed on the Ukrainian government portal, the government adopted the Resolution No. 558 dated 08.08.2016 “On Amendments To The Procedure For State Registration (Re-Registration) Of Medicinal Products” in order to unify the legal regulation of the state registration of medicinal products. The proposed changes are a reflection of innovations aimed at expanding the list of medicinal products subject to the simplified state registration procedure that were previously made by amending Article 9 of the Law of Ukraine “On Medicinal Products”.
Specifically, after making such amendments, medicinal products registered by a competent authority of the USA, Switzerland, Japan, Australia, Canada, as well as under the centralized procedure by the competent authority of the European Union for use in the territory of such states or member states of the European Union, have also become subject to the simplified procedure registration.
The simplified procedure for such medicinal products envisages that:
Please note that the information regarding the adoption of the Resolution was placed on the Ukrainian government portal, but the Resolution has not become effective and corresponding changes have not yet been applied to the current Procedure for State Registration (Re-Registration) of Medicinal Products.
The event focused on the transformation of Ukraine's intellectual property sector on its path toward European integration.
Improving access to safe and affordable medicines for the Ukrainian population is one of the Government of Ukraine's top priorities. SAFEMed Activity (2017-2025) has supported this effort by appIying health system strengthening best practices.
The Ministry of Health website has posted a notice about the release of a revised draft order of the Ministry of Health ‘On Approval of Amendments to Certain Re
On 25 September, a webinar was held on the topic: ‘180 days of new drug price regulation. Results, prospects and practical advice.’ The event was organized by LA Law Firm in partnership with Proxima Research International.